CHM 4.17% 1.2¢ chimeric therapeutics limited

I think the next news should be the dosing of newly diagnosed...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,428 Posts.
    lightbulb Created with Sketch. 2059
    I think the next news should be the dosing of newly diagnosed AML patients withour NK cell drug in combination with SOC. This is important, as getting the drug used early in the treatment will quickly show any benefit. This should happen before the end of the year.
    There may also be another up to the phase 1a data in GBM, end of this year early next.

    Next year, if all 4 trials get underway there will be plenty of announcements mid year to end of year. Potentially the progressing into a phase 2b accelerated approval trial for GBM.

    Lots to be excited about here.
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.2¢
Change
-0.001(4.17%)
Mkt cap ! $11.44M
Open High Low Value Volume
1.1¢ 1.2¢ 1.1¢ $2.657K 235.9K

Buyers (Bids)

No. Vol. Price($)
7 1428738 1.1¢
 

Sellers (Offers)

Price($) Vol. No.
1.2¢ 1161817 4
View Market Depth
Last trade - 11.54am 06/11/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.